Indivior (NASDAQ:INDV) CAO Woodrow Anderson Acquires 1,500 Shares

Indivior PLC (NASDAQ:INDV) CAO Woodrow Anderson acquired 1,500 shares of Indivior stock in a transaction dated Thursday, August 27th. The shares were bought at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the transaction, the chief accounting officer owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. The trade was a 5.74% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Indivior Trading Down 1.5%

INDV traded down $0.53 during trading on Thursday, hitting $35.30. 1,220,385 shares of the company traded hands, compared to its average volume of 2,195,336. The company has a market cap of $4.17 billion, a PE ratio of 12.65 and a beta of 0.86. The stock’s 50-day simple moving average is $39.46 and its two-hundred day simple moving average is $36.00. Indivior PLC has a 1 year low of $22.22 and a 1 year high of $42.81.

Indivior (NASDAQ:INDV) last issued its earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.The firm had revenue of $343.00 million for the quarter. Equities analysts expect that Indivior PLC will post 3.66 EPS for the current year.

Institutional Trading of Indivior

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its position in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares during the period. Fuller & Thaler Asset Management Inc. grew its stake in shares of Indivior by 101.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock valued at $228,611,000 after buying an additional 3,201,639 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Indivior by 57.9% during the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after acquiring an additional 2,008,078 shares during the last quarter. California State Teachers Retirement System purchased a new position in Indivior during the 2nd quarter valued at $201,163,000. Finally, State Street Corp increased its stake in Indivior by 65.5% in the fourth quarter. State Street Corp now owns 4,659,281 shares of the company’s stock worth $167,175,000 after purchasing an additional 1,844,532 shares during the period. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on INDV. Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, August 21st. Craig Hallum restated a “buy” rating and issued a $53.00 target price on shares of Indivior in a report on Tuesday, August 4th. Finally, Barclays lowered their price target on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $45.17.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.